CommercialCoverageMedium impact
Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) 7.02.02
Excellus BlueCross BlueShield·Oncology, Hematology, Pediatrics·Transplants
Effective date
Feb 19, 2026
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield has updated their policy for Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT), defining specific medical conditions and criteria that make the procedure medically appropriate versus investigational. The policy covers 16 categories of conditions including various leukemias, lymphomas, bone marrow failure syndromes, and immune deficiencies.
Action Required
Before February 19, 2026: Billing team must review all pending and future Allogeneic HSCT cases to ensure they meet the specific indication criteria listed in the updated policy. Verify multidisciplinary team documentation includes all required clinical evaluation components (diagnosis confirmation, comorbidity assessment, performance status scores, cardiac/pulmonary assessments, lab tests, and age-appropriate screenings). Cases not meeting the 16 approved indication categories will be considered investigational and likely denied.